Current Opinion in Pulmonary Medicine最新文献_第6页

Editorial introductions. 编辑介绍。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.1097/MCP.0000000000001107

引用次数: 0

What causes cough in pulmonary fibrosis, and how should we treat it? 肺纤维化患者咳嗽的原因是什么？

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-06-24 DOI: 10.1097/MCP.0000000000001087

Katherine J Myall, Peter S P Cho, Surinder S Birring

引用次数: 0

Big data in sarcoidosis. 肉样瘤病的大数据。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-07-05 DOI: 10.1097/MCP.0000000000001102

Natalia V Rivera

{"title":"Big data in sarcoidosis.","authors":"Natalia V Rivera","doi":"10.1097/MCP.0000000000001102","DOIUrl":"10.1097/MCP.0000000000001102","url":null,"abstract":"Purpose of review: This review provides an overview of recent advancements in sarcoidosis research, focusing on collaborative networks, phenotype characterization, and molecular studies. It highlights the importance of collaborative efforts, phenotype characterization, and the integration of multilevel molecular data for advancing sarcoidosis research and paving the way toward personalized medicine.Recent findings: Sarcoidosis exhibits heterogeneous clinical manifestations influenced by various factors. Efforts to define sarcoidosis endophenotypes show promise, while technological advancements enable extensive molecular data generation. Collaborative networks and biobanks facilitate large-scale studies, enhancing biomarker discovery and therapeutic protocols.Summary: Sarcoidosis presents a complex challenge due to its unknown cause and heterogeneous clinical manifestations. Collaborative networks, comprehensive phenotype delineation, and the utilization of cutting-edge technologies are essential for advancing our understanding of sarcoidosis biology and developing personalized medicine approaches. Leveraging large-scale epidemiological resources and biobanks and integrating multilevel molecular data offer promising avenues for unraveling the disease's heterogeneity and improving patient outcomes.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"561-569"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applications of artificial intelligence in computed tomography imaging for phenotyping pulmonary hypertension. 人工智能在肺动脉高压表型计算机断层扫描成像中的应用。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-07-09 DOI: 10.1097/MCP.0000000000001103

Michael J Sharkey, Elliot W Checkley, Andrew J Swift

{"title":"Applications of artificial intelligence in computed tomography imaging for phenotyping pulmonary hypertension.","authors":"Michael J Sharkey, Elliot W Checkley, Andrew J Swift","doi":"10.1097/MCP.0000000000001103","DOIUrl":"10.1097/MCP.0000000000001103","url":null,"abstract":"Purpose of review: Pulmonary hypertension is a heterogeneous condition with significant morbidity and mortality. Computer tomography (CT) plays a central role in determining the phenotype of pulmonary hypertension, informing treatment strategies. Many artificial intelligence tools have been developed in this modality for the assessment of pulmonary hypertension. This article reviews the latest CT artificial intelligence applications in pulmonary hypertension and related diseases.Recent findings: Multistructure segmentation tools have been developed in both pulmonary hypertension and nonpulmonary hypertension cohorts using state-of-the-art UNet architecture. These segmentations correspond well with those of trained radiologists, giving clinically valuable metrics in significantly less time. Artificial intelligence lung parenchymal assessment accurately identifies and quantifies lung disease patterns by integrating multiple radiomic techniques such as texture analysis and classification. This gives valuable information on disease burden and prognosis. There are many accurate artificial intelligence tools to detect acute pulmonary embolism. Detection of chronic pulmonary embolism proves more challenging with further research required.Summary: There are numerous artificial intelligence tools being developed to identify and quantify many clinically relevant parameters in both pulmonary hypertension and related disease cohorts. These potentially provide accurate and efficient clinical information, impacting clinical decision-making.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"464-472"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic background of pulmonary (vascular) diseases - how much is written in the codes? 肺（血管）疾病的遗传背景--代码中写了多少？

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-06-24 DOI: 10.1097/MCP.0000000000001090

Christina A Eichstaedt, Simon O Haas, Memoona Shaukat, Ekkehard Grünig

{"title":"Genetic background of pulmonary (vascular) diseases - how much is written in the codes?","authors":"Christina A Eichstaedt, Simon O Haas, Memoona Shaukat, Ekkehard Grünig","doi":"10.1097/MCP.0000000000001090","DOIUrl":"10.1097/MCP.0000000000001090","url":null,"abstract":"Purpose of review: To provide a comprehensive overview of the underlying genetic defects of pulmonary (vascular) diseases and novel treatment avenues.Recent findings: Pulmonary arterial hypertension (PAH) is the prime example of a pulmonary vascular disease, which can be caused by genetic mutations in some patients. Germline mutations in the BMPR2 gene and further genes lead to vessel remodelling, increase of pulmonary vascular resistance and onset of heritable PAH. The PAH genes with the highest evidence and strategies for genetic testing and counselling have been assessed and evaluated in 2023 by international expert consortia. Moreover, first treatment options have just arisen targeting the molecular basis of PAH.Summary: Apart from PAH, this review touches on the underlying genetic causes of further lung diseases including alpha 1 antitrypsin deficiency, cystic fibrosis, familial pulmonary fibrosis and lymphangioleiomyomatosis. We point out the main disease genes, the underlying pathomechanisms and novel therapies trying not only to relieve symptoms but to treat the molecular causes of the diseases.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"429-436"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating the assessment of quality of life in care and research in pulmonary fibrosis. 将生活质量评估纳入肺纤维化护理和研究。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-07-01 DOI: 10.1097/MCP.0000000000001095

Kerri I Aronson, Jeffrey J Swigris, Marlies Wijsenbeek

{"title":"Integrating the assessment of quality of life in care and research in pulmonary fibrosis.","authors":"Kerri I Aronson, Jeffrey J Swigris, Marlies Wijsenbeek","doi":"10.1097/MCP.0000000000001095","DOIUrl":"10.1097/MCP.0000000000001095","url":null,"abstract":"Purpose of review: Pulmonary fibrosis (PF) negatively influences health-related quality of life (HRQOL). Patients living with PF have voiced the desire for a focus on symptoms and HRQOL in both disease monitoring and treatment decisions.Recent findings: Currently available disease modifying treatments do little to impact HRQOL. Newer studies evaluating pharmacologic and nonpharmacologic therapies targeting symptoms and HRQOL in PF have been conducted with some promising results. There is increasing recognition of the importance of incorporating HRQOL as a higher tier endpoint in clinical trials. Disease-specific measure of HRQOL have been developed for those living with PF, and there is ongoing work to better understand the validity and reliability characteristics of these tools. In addition to research, there is recognition of the potential benefits of measuring HRQOL and symptoms in clinical practice in facilitate integrating patient perspective into care and allow for more personalized treatment approaches.Summary: There is increased momentum to discover treatments that impact HRQOL in PF. More work is desperately needed to identify better treatment targets, and to incorporate HRQOL and symptoms as higher tier endpoints in clinical trials. Further work is also needed to address the practicalities of integrating HRQOL measurement into clinical care.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"508-515"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pulmonary vascular disease in chronic lung diseases: cause or comorbidity? 慢性肺病中的肺血管疾病：病因还是并发症？

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-07-03 DOI: 10.1097/MCP.0000000000001091

Isabel Blanco, Rodrigo Torres-Castro, Joan Albert Barberà

{"title":"Pulmonary vascular disease in chronic lung diseases: cause or comorbidity?","authors":"Isabel Blanco, Rodrigo Torres-Castro, Joan Albert Barberà","doi":"10.1097/MCP.0000000000001091","DOIUrl":"10.1097/MCP.0000000000001091","url":null,"abstract":"Purpose of review: To provide timely and relevant insights into the complex relationship between pulmonary vascular disease (PVD) and chronic lung disease (CLD), focusing on the causative and consequential dynamics between these conditions.Recent findings: There are shared pathogenic mechanisms between pulmonary arterial hypertension (PAH) and group 3 pulmonary hypertension, including altered expression of mediators and growth factors implicated in both conditions. Factors such as hypoxia, hypoxemia, and hypercapnia also contribute to pulmonary vascular remodelling and endothelial dysfunction. However, the role of hypoxia as the sole driver of pulmonary hypertension in CLD is being reconsidered, particularly in chronic obstructive pulmonary disease (COPD), with evidence suggesting a potential role for cigarette smoke products in initiating pulmonary vascular impairment. On the other hand, interstitial lung disease (ILD) encompasses a group of heterogeneous lung disorders characterized by inflammation and fibrosis of the interstitium, leading to impaired gas exchange and progressive respiratory decline, which could also play a role as a cause of pulmonary hypertension.Summary: Understanding the intricate interplay between the pulmonary vascular compartment and the parenchymal and airway compartments in respiratory disease is crucial for developing effective diagnostic and therapeutic strategies for patients with PVD and CLD, with implications for both clinical practice and research.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"437-443"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current hot topics in pulmonary hypertension. 当前肺动脉高压的热门话题。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.1097/MCP.0000000000001100

Gabor Kovacs, Katarina Zeder

引用次数: 0

The future of clinical trials in idiopathic pulmonary fibrosis. 特发性肺纤维化临床试验的未来。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-07-04 DOI: 10.1097/MCP.0000000000001099

Paolo Spagnolo, Toby M Maher

{"title":"The future of clinical trials in idiopathic pulmonary fibrosis.","authors":"Paolo Spagnolo, Toby M Maher","doi":"10.1097/MCP.0000000000001099","DOIUrl":"10.1097/MCP.0000000000001099","url":null,"abstract":"Purpose of review: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis and limited therapeutic options. A multitude of promising compounds are currently being investigated; however, the design and conductance of late-phase clinical trials in IPF has proven particularly challenging.Recent findings: Despite promising phase 2 data, ziritaxestat, an autotaxin inhibitor, pentraxin-2, an endogenous protein that regulates wound healing and fibrosis, and pamrevlumab, a human monoclonal antibody against connective tissue growth factor, failed to show efficacy in phase 3 trials. Endpoint selection is critical for the design, execution, and success of clinical trials; recently, attention has been paid to the assessment of how patients feel, function, and survive with the aim of aligning scientific objectives and patient needs in IPF. External control arms are control patients that derive from historical randomized controlled trials, registries, or electronic health records. They are increasingly used to assess treatment efficacy in clinical trials owing to their potential to reduce study duration and cost and increase generalizability of findings.Summary: Advances in study design, end point selection and statistical analysis, and innovative strategies for more efficient enrolment of study participants have the potential to increase the likelihood of success of late-phase clinical trials in IPF.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"494-499"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac sarcoidosis and neurosarcoidosis - multidisciplinary approach for diagnosis. 心脏肉样瘤病和神经肉样瘤病--多学科诊断方法。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-07-03 DOI: 10.1097/MCP.0000000000001097

Vasileios Kouranos, Rakesh Sharma, Athol Wells, Victoria Singh-Curry

{"title":"Cardiac sarcoidosis and neurosarcoidosis - multidisciplinary approach for diagnosis.","authors":"Vasileios Kouranos, Rakesh Sharma, Athol Wells, Victoria Singh-Curry","doi":"10.1097/MCP.0000000000001097","DOIUrl":"10.1097/MCP.0000000000001097","url":null,"abstract":"Purpose of review: The current review aims to highlight the role of multidisciplinary approach in the diagnosis of patients with cardiac and neurosarcoidosis. Multidisciplinary approach integrates the available clinical information, imaging and histopathological results aiming to reach a definite or at least provisional diagnosis and allow appropriate management. Multidisciplinary approach is the reference standard for diagnosis of interstitial lung disease and should be strongly considered in complex clinical conditions such as cardiac sarcoidosis (CS) and neurosarcoidosis.Recent findings: Histopathological confirmation of noncaseating granulomatous inflammation provides a definite diagnosis of sarcoidosis involving any organ. However, a provisional high confidence or even definite clinical diagnosis can be reached using multidisciplinary evaluation of all available evidence. The diagnosis of cardiac sarcoidosis and neurosarcoidosis requires the integration of different expertise based on the current diagnostic criteria sets. Identifying typical or at least compatible patterns on advanced imaging modalities (CMR and Fluro-Deoxy-Glucose Positron Emission Tomography (FDG-PET)) seems key for the diagnosis of CS, while a confident diagnosis of extra-cardiac disease supports an at least provisional diagnosis. Similarly, in neurosarcoidosis integrating compatible MRI appearances and cerebrospinal fluid results in patients with systemic sarcoidosis allows an at least provisional diagnosis. Exclusion of alternative differential diagnoses is crucial and requires high clinical suspicion, imaging review expertise and appropriate tests performance.Summary: There have been considerable advances in the diagnostic approach of patients with cardiac and neurosarcoidosis. Multidisciplinary approach for both diagnosis and management is required to reach a confident clinical diagnosis and should be applied when possible.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"540-550"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0